30194-54-8

Basic information

• Product Name: 2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine
• Synonyms: 2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine;2-(4-Pyridin-2-yl-piperazin-1-yl)-ethylamine
• CAS NO: 30194-54-8
• Molecular Formula: C₁₁H₁₈N₄
• Molecular Weight: 206.29
• Product Categories: pharmacetical
• Mol File: 30194-54-8.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 358°Cat760mmHg
• Flash Point: 170.3°C
• Appearance: /
• Density: 1.101g/cm³
• Vapor Pressure: 2.62E-05mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: 2-8°C
• PKA: 10.11±0.10(Predicted)
• CAS DataBase Reference: 2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine(30194-54-8)
• EPA Substance Registry System: 2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine(30194-54-8)

Safety Data

• Hazardous Substances Data: 30194-54-8(Hazardous Substances Data)

Usage

General Description

2-(4-Pyridin-2-ylpiperazin-1-yl)ethanamine, also known as Vabicaserin, is a chemical compound that belongs to the class of piperazine derivatives. It is a serotonin receptor agonist, specifically targeting the 5-HT2C receptor. Vabicaserin has been studied for its potential therapeutic effects in the treatment of various psychiatric and neurological disorders, including schizophrenia, anxiety, and depression. It has also been investigated for its potential role in modulating food intake and weight regulation. The compound is still under research and development, with potential applications in the field of mental health and neuropharmacology.

InChI:InChI=1/C11H18N4/c12-4-6-14-7-9-15(10-8-14)11-3-1-2-5-13-11/h1-3,5H,4,6-10,12H2

Upstream product

• 302557-33-1 benzyl N-[2-(piperazin-1-yl)ethyl]carbamate 
• 192130-34-0 tert-butyl 4-(2-aminoethyl)piperazine-1-carboxylate 
• 33386-11-7 2-(4-(pyridin-2-yl)piperazin-1-yl)acetonitrile 
• 34803-66-2 1-(2-pyridyl)piperazine 
• 117992-73-1 2-(2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)isoindoline-1,3-dione 

Downstream Products

• 1240266-65-2 C₂₄H₃₁N₅O*ClH 
• 697287-72-2 [2-(4-pyridin-2-yl-piperazin-1-yl)-ethyl]-[3-(2-trifluoromethyl-phenyl)-isoxazol-5-ylmethyl]-amine 

Relevant articles and documents

COMPOUNDS USEFUL FOR INHIBITING RAF DIMERS

The disclosure provides compounds of Formula I (Formula I) (c) And the pharmaceutically acceptable salts thereof. The A, B, C, and D rings and the variables, RA, RB, RC, RD, L0, L1, L2

Further delineation of hydrophobic binding sites in dopamine D 2/D3 receptors for N-4 substituents on the piperazine ring of the hybrid template 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5, 6,7,8-tetrahydro-naphthalen-2-ol

Here we report a structure-activity relationship (SAR) study of analogues of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro- naphthalen-2-ol. Our SAR is focused on introduction of various substitutions in the piperazine ring of the hybrid template. The goal behind this study is to delineate the nature of the binding pocket for N-aryl substitution in the piperazine ring by observing the effect of various hydrophobic and other heteroaromatic substitutions on binding affinity (Ki), as measured with tritiated spiperone and HEK-293 cells expressing either D2 or D3 receptors. Functional activity of selected compounds was assessed with the GTPγS binding assay. Compound 8d was the most selective for the D3 receptor in the spiperone binding assay. An interesting similarity in binding affinity was observed between isoquinoline derivative D-301 and the 2-substituted pyridine derivative 8d, suggesting the importance of relative spatial relationships between the N-atom of the ligand and the molecular determinants of the binding pocket in D2/D3 receptors. Functional activity assays demonstrated high potency and selectivity of (+)-8a and (-)-28b (D2/D3 (ratio of EC50): 105 and 202, respectively) for the D3 receptor and both compounds were more selective compared to the reference drug ropinirole (D2/D3 (ratio of EC50): 29.5).

3-IMIDAZOLYL-INDOLES FOR THE TREATMENT OF PROLIFERATIVE DISEASES

The invention relates to 3-heterocyclyl indolyl compounds capable of inhibiting the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively, said compounds having the formula (I) wherein R1, R2, R3, R4, RA, Y and Y are as defined in the specification. Due to their activity, the compounds are useful in the treatment of various disorders and diseases mediated by the activity of MDM2 and/or MDM4, or variants thereof, such as inflammatory or proliferative diseases or in the protection of cells.